The U.S. Food and Drug Administration (FDA) has approved GSK’s Blujepa (gepotidacin), a groundbreaking oral antibiotic for treating uncomplicated urinary tract infections (uUTIs) in adult women and ...

Blujepa, the first new oral UTI antibiotic in 30 years, offers hope against antibiotic-resistant infections, improving ...

Blujepa sets itself apart from nitrofurantoin as well as newer ... due to its unique mechanism of action and potential to overcome antimicrobial resistance, a growing threat that makes many ...